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I N T R O D U C T I O N
In contrast to many other Western countries there is still
a debate in the Netherlands about whether pneumococcal
vaccination is of benefit for healthy elderly people. In
1982 the Health Council of the Netherlands issued a
report on this subject and concluded that there was no
scientific background for vaccinating people only based
on age over 65 years.1 In the meantime pneumococcal
vaccination for the elderly has been introduced in a
number of Western countries and this was the reason for
preparing a new report within the Health Council.2
Pneumococcal vaccination was introduced before the
Second World War.3 Vaccination has been very successful
in younger populations with healthy individuals living in
special conditions with a high incidence of pneumococcal
disease, such as young miners in South Africa and people
living in the highlands of New Guinea.4 Later on, there
appeared to be more difficulties in elderly people and
people with conditions influencing their immune status.
Early vaccine was based on 2-4 pneumococcal serotypes.
Later 6-13 and 14-valent vaccines were developed. At this
moment, 23-valent polysaccharide vaccines are mainly
used. For children a special vaccine has been developed
with an antigen conjugated to protein. A 7-valent conjugate
vaccine is currently being used. It will probably not be
possible to develop a more than 10-valent vaccine in the
near future.
After vaccination, protection against infection starts after
two to three weeks. The duration of the protection is
uncertain. In healthy adults, antibody is present up to five
years after vaccination. 
Local erythema and pain at the site of injection occur
frequently.5 Systematic reactions are rare. These side
effects are more frequent in patients who have had a
pneumococcal vaccination with an earlier vaccination
within three years and in patients with a history of a
pneumococcal infection during the three years before
the vaccination.6
Pneumococcal vaccination is often combined with 
vaccination against influenza. The latter is given each
year, pneumococcal vaccination every five years. There is
no problem in giving both vaccinations at the same time
if different injection sites are used. 
It could be that adding pneumococcal vaccination to the
regular vaccination against influenza in the Netherlands
would lower the adherence to the influenza vaccination
programme. Opstelten and colleagues did a pilot study in
Dutch general practices and found no significant decline
in the number of older patients coming for their yearly
flu vaccinations.7
S P E C I A L  I N D I C A T I O N S  F O R  
P N E U M O C O C C A L  V A C C I N A T I O N
A small but important group of patients that is at high
risk for serious pneumococcal disease is the group of
patients without a (functional) spleen.8 The number of
asplenic patients in the Netherlands is unknown, but
every year approximately 1000 splenectomies are performed
after a trauma or due to disease. One out of 20 asplenic
patients will have a life-threatening infection once in
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their lives. More than 50% of these patients will die
due to these infections within two days after the first
symptoms.9
In the earlier advice of the Dutch Health Council in 1982
pneumococcal vaccination was pressingly recommended
for asplenic patients. Revaccination should take place
every five years. Besides pneumococcal vaccinations these
patients should have antibiotics available to take in cases
of fever.8
Pneumococcal vaccination is also recommended for patients
with sickle-cell anaemia who can have afunctional spleen
function due to multiple spleen infarctions and patients
with leakage of cerebrospinal fluid.
Vaccinations should be considered for patients with
Hodgkin’s and non-Hodgkin’s lymphoma disease, patients
with HIV, myeloma, chronic lymphatic leukaemia, auto-
immune disease, renal disease, alcoholism, cirrhosis and
patients receiving immunosuppressants or recipients of
transplants of organs or bone marrow.
I M P L E M E N T A T I O N  O F  I N F L U E N Z A
V A C C I N A T I O N  I N  T H E  E L D E R L Y  
In the Netherlands, vaccination against influenza has
been implemented successfully. Before 1994, influenza
vaccination was only recommended for patients at high
risk. Vaccination was carried out in patients with chronic
lung disease, diabetes and chronic heart disease. Most
vaccinations were given by GPs. However, there was no
structured programme to identify all patients at risk and
to invite them to receive their vaccinations. In 1994 the
Minister of Health advised vaccinating all persons of 65
years and older. A national programme was introduced to
help GPs to identify patients at risk using their computer
systems. A reasonable imbursement was given to all GPs
involved. In the following years, the vaccination rate
increased to up to 76% of the patients at risk in 2000.10
In that year 17.1% of the total population in the
Netherlands was vaccinated.
E V I D E N C E  F O R  T H E  E F F I C A C Y  O F
P N E U M O C O C C A L  V A C C I N A T I O N
The ideal way to prove that pneumococcal vaccination
gives protection against death or serious morbidity due to
pneumococcal disease would be the randomised clinical
trial (RCT). To address the question as to whether pneumo-
coccal vaccination should be introduced in the Netherlands
for otherwise healthy persons of 65 years and older
together with a vaccination against influenza, there is
only one RCT that can be used for this special population.11
In this study only a subgroup of patients with other related
risk factors had benefit from pneumococcal vaccination.
Assendelft and co-workers of the Dutch Cochrane Centre
performed an assessment of the available literature. In this
issue of this journal they report their results with their
conclusions that there is insufficient convincing evidence in
favour of the introduction of the pneumococcus vaccination
as a supplement to the influenza vaccination for healthy
persons 65 years of age or older.12
This does not mean that it is proven that pneumococcal
vaccinations have no benefit. There still is circumstantial
evidence that there are benefits. In a recent large retro-
spective cohort study with almost 50,000 patients there
was a reduction in the risk of pneumococcal bacteraemia
(hazard ratio 0.56 (0.33 - 0.93)) although there was a
small increase in the number of patients who needed
hospitalisation for pneumonia.13 Only a large randomised
controlled trial in this special population using the right
endpoints can be conclusive. 
Now discussion becomes a question of belief. Do we
harm a number of people when we do not vaccinate
them or are we using our energy and money for the
wrong purpose? 
In many countries there are official recommendations for
pneumococcal vaccination of the elderly.14 Therefore in
these countries placebo-controlled studies are hardly
possible due to ethical considerations. 
In the United States an 18% decline in the number of cases
of invasive pneumococcal disease in people older than 65
years of age has recently been reported.15 This might be
due to the introduction of the conjugate pneumococcal
vaccine for children (herd immunity), but these ideas are
not based on data.16
T H E  H E A L T H  C O U N C I L  R E P O R T  2 0 0 3
Based on the results of the meta-analysis of the Dutch
Cochrane Centre and after numerous and extensive
deliberations the Health Council of the Netherlands decided
that there is no conclusive evidence for the effectiveness
of pneumococcal vaccination in addition to influenza 
vaccination in healthy persons 65 years or older.2 The
council recommended starting a prospective study in the
Netherlands with healthy elderly vaccinated for influenza
who are randomised to receive an additional pneumococcal
vaccination. The results of this study or comparable
studies could provide the argument to make new 
recommendations.
The success of the influenza vaccination programme in
the Netherlands performed in general practice shows
that if enough evidence does become available for pneu-
mococcal vaccination in the future, general practice will
be the best place to execute this additional vaccination
programme.
Van den Bosch. Comment to pneumococcal vaccination for healthy elderly.
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Professor Van den Bosch was a member of the
Committee of the Health Council of the Netherlands that
prepared the recent report on pneumococcal vaccination.2
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